Scholarlink

Background <p>17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) is a key placental steroidogenic enzyme that converts estrone to estradiol. Prior studies have suggested that reduced placental or circulating HSD17B1 is associated with preeclampsia (PE), but its position within the broader transcriptomic landscape and its relationship to immune changes remain incompletely characterized.</p> Methods <p>Placental transcriptomic data from GSE75010 (77 controls and 80 PE placentas) were analyzed to identify differentially expressed genes (DEGs). Summary data-based Mendelian randomization (SMR) integrating eQTLGen cis-eQTL data with FinnGen preeclampsia summary statistics was then used to prioritize candidate genes. Immune cell infiltration was explored by CIBERSORT using the placental bulk transcriptomic matrix. Independent validation was performed in a clinical cohort comprising 96 women with PE and 96 normotensive pregnant controls by maternal plasma ELISA at 17–18 weeks of gestation and placental RT-qPCR at delivery.</p> Results <p>DEG analysis identified 207 genes (152 upregulated and 55 downregulated) in PE placentas. HSD17B1 was the single overlapping candidate prioritized by both DEG and SMR analyses, and genetically predicted higher HSD17B1 expression showed an inverse association with PE risk under nominal SMR significance criteria. In the validation cohort, plasma HSD17B1 was lower in women with PE than in controls, and placental HSD17B1 mRNA was also significantly reduced. Exploratory immune deconvolution showed altered proportions of plasma cells, CD8 T cells, regulatory T cells, resting CD4 memory T cells, resting mast cells, eosinophils, and neutrophils in PE placentas; HSD17B1 expression correlated with several of these subsets.</p> Conclusions <p>HSD17B1 is consistently downregulated in PE across public placental transcriptomic data and an independent validation cohort. When interpreted together with prior literature on miR-210/miR-518c, ESRRG signaling, and trophoblast differentiation, these findings support HSD17B1 as a biologically plausible PE-associated marker. However, the present study does not establish whether reduced HSD17B1 is a cause or a consequence of PE, and the immune findings should be regarded as exploratory.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Reduced HSD17B1 expression in preeclampsia: integrated transcriptomic, summary Mendelian randomization, immune deconvolution, and experimental validation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Keng Ling,
  • Minping Hong,
  • Liqin Jin,
  • Ai Ling,
  • Jianguo Wang

摘要

Background

17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) is a key placental steroidogenic enzyme that converts estrone to estradiol. Prior studies have suggested that reduced placental or circulating HSD17B1 is associated with preeclampsia (PE), but its position within the broader transcriptomic landscape and its relationship to immune changes remain incompletely characterized.

Methods

Placental transcriptomic data from GSE75010 (77 controls and 80 PE placentas) were analyzed to identify differentially expressed genes (DEGs). Summary data-based Mendelian randomization (SMR) integrating eQTLGen cis-eQTL data with FinnGen preeclampsia summary statistics was then used to prioritize candidate genes. Immune cell infiltration was explored by CIBERSORT using the placental bulk transcriptomic matrix. Independent validation was performed in a clinical cohort comprising 96 women with PE and 96 normotensive pregnant controls by maternal plasma ELISA at 17–18 weeks of gestation and placental RT-qPCR at delivery.

Results

DEG analysis identified 207 genes (152 upregulated and 55 downregulated) in PE placentas. HSD17B1 was the single overlapping candidate prioritized by both DEG and SMR analyses, and genetically predicted higher HSD17B1 expression showed an inverse association with PE risk under nominal SMR significance criteria. In the validation cohort, plasma HSD17B1 was lower in women with PE than in controls, and placental HSD17B1 mRNA was also significantly reduced. Exploratory immune deconvolution showed altered proportions of plasma cells, CD8 T cells, regulatory T cells, resting CD4 memory T cells, resting mast cells, eosinophils, and neutrophils in PE placentas; HSD17B1 expression correlated with several of these subsets.

Conclusions

HSD17B1 is consistently downregulated in PE across public placental transcriptomic data and an independent validation cohort. When interpreted together with prior literature on miR-210/miR-518c, ESRRG signaling, and trophoblast differentiation, these findings support HSD17B1 as a biologically plausible PE-associated marker. However, the present study does not establish whether reduced HSD17B1 is a cause or a consequence of PE, and the immune findings should be regarded as exploratory.